A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Recruiting now · Phase 1/Phase 2

Conditions studied: Myelofibrosis

In brief

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

Key facts

Study ID

NCT04176198

Run by

Sumitomo Pharma America, Inc.

People needed

240

Starts

2019-12-16

Expected to finish

2030-04-30

Last updated by the study team

2026-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Medical University of South Carolina — Charleston, South Carolina, United States (enrolling)
• City of Hope — Duarte, California, United States (enrolling)
• University of Alabama — Birmingham, Alabama, United States (enrolling)
• Hoag Family Cancer Institute — Newport Beach, California, United States (enrolling)
• Blood Cancer Center — Denver, Colorado, United States (enrolling)
• Yale School of Medicine — New Haven, Connecticut, United States (enrolling)
• University of Southern California — Los Angeles, California, United States (enrolling)
• The University of Arizona Cancer Center — Tucson, Arizona, United States (enrolling)
• Baptist Health - Miami Cancer Institute — Miami, Florida, United States (enrolling)
• Emory University — Atlanta, Georgia, United States (enrolling)
• University of Chicago — Chicago, Illinois, United States (enrolling)
• University of Maryland — Baltimore, Maryland, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• University of Michigan — Ann Arbor, Michigan, United States (enrolling)
• University of Minnesota — Minneapolis, Minnesota, United States (enrolling)
• Washington University of Medicine — St Louis, Missouri, United States (enrolling)
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
• University of Miami — Miami, Florida, United States (enrolling)
• Icahn School of Medicine at Mount Sinai — New York, New York, United States (enrolling)
• Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
• Weill Cornell Medical Center — New York, New York, United States (enrolling)
• Montefiore Cancer Center — The Bronx, New York, United States (enrolling)
• Duke Cancer Institute — Durham, North Carolina, United States (enrolling)
• Ohio State University — Columbus, Ohio, United States (enrolling)
• Tri-Star Centennial Medical Center — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.